# MoonLake Immunotherapeutics Prepares FDA Application for Sonelokimab

- URL: https://stocks.freetheai.org/news/moonlake-immunotherapeutics-prepares-fda-application-for-sonelokimab-065d94
- Published: 2026-10-18T14:49:00Z
- Category: analyst_ratings; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:MLTX](https://stocks.freetheai.org/symbols/NASDAQ-MLTX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

MoonLake Immunotherapeutics (NASDAQ:MLTX) is preparing to submit a biologics license application to the U.S. Food and Drug Administration for sonelokimab, a treatment for hidradenitis suppurativa. Company management expresses high confidence that federal regulators will accept the filing for review, though official filing acceptance will not guarantee final approval. Meanwhile, MLTX shares fell 6.92% today to 9.55 USD.

A decision by regulators to accept the application could act as a catalyst for the company in the near term. Analysts hold a sector perform rating and speculative-risk designation on the stock, alongside a $17 price target. While MoonLake outlines potential commercial benefits over existing treatments like bimekizumab—including a simpler, cheaper initial dosing schedule and lower rates of side effects like dermatitis and candidiasis—financial analysts emphasize that clearer proof of market adoption is necessary for sustained stock performance.

Investors should monitor upcoming updates regarding the filing status and potential review timelines. Management estimates only a 20% chance of obtaining a priority review due to regulatory resource constraints, suggesting a standard review schedule is more probable. Future milestones will center on official application acceptance and further evidence demonstrating the drug's competitive position in the market.

## Key points

- MoonLake Immunotherapeutics plans to submit an FDA application for sonelokimab to treat hidradenitis suppurativa.
- Management estimates a 20% chance of receiving priority review from the FDA due to agency resource constraints.
- MoonLake highlights advantages over rival drug bimekizumab, including lower initial costs and reduced side effects.
- Analysts maintain a sector perform rating and a $17 price target on NASDAQ:MLTX shares, which fell 6.92% to 9.55 USD.

## Questions and answers

### What is MoonLake Immunotherapeutics seeking FDA approval for?

MoonLake Immunotherapeutics is seeking approval for sonelokimab, a biologic treatment designed for hidradenitis suppurativa.

### What is the price target for MoonLake Immunotherapeutics stock?

RBC Capital Markets maintains a $17 price target and a sector perform rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) shares.

### What are the expected advantages of sonelokimab over bimekizumab?

MoonLake outlines benefits including a simpler and less expensive initial treatment regimen, less dermatitis, less severe candidiasis, and improved patient access compared to bimekizumab.